RU2010111116A - Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы - Google Patents
Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы Download PDFInfo
- Publication number
- RU2010111116A RU2010111116A RU2010111116/10A RU2010111116A RU2010111116A RU 2010111116 A RU2010111116 A RU 2010111116A RU 2010111116/10 A RU2010111116/10 A RU 2010111116/10A RU 2010111116 A RU2010111116 A RU 2010111116A RU 2010111116 A RU2010111116 A RU 2010111116A
- Authority
- RU
- Russia
- Prior art keywords
- double
- stranded molecule
- prostate cancer
- seq
- pkib
- Prior art date
Links
- 101000978006 Homo sapiens cAMP-dependent protein kinase inhibitor beta Proteins 0.000 title claims abstract 16
- 102100023516 cAMP-dependent protein kinase inhibitor beta Human genes 0.000 title claims abstract 11
- 101000635408 Homo sapiens Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 Proteins 0.000 title claims abstract 10
- 102100031009 Inactive N-acetylated-alpha-linked acidic dipeptidase-like protein 2 Human genes 0.000 title claims abstract 10
- 206010060862 Prostate cancer Diseases 0.000 title claims 18
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims 18
- 238000003745 diagnosis Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 30
- 230000000692 anti-sense effect Effects 0.000 claims abstract 16
- 230000014509 gene expression Effects 0.000 claims abstract 14
- 230000000295 complement effect Effects 0.000 claims abstract 12
- 239000002773 nucleotide Substances 0.000 claims abstract 12
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 12
- 108091081021 Sense strand Proteins 0.000 claims abstract 8
- 108091033319 polynucleotide Proteins 0.000 claims abstract 7
- 239000002157 polynucleotide Substances 0.000 claims abstract 7
- 102000040430 polynucleotide Human genes 0.000 claims abstract 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract 5
- 201000011510 cancer Diseases 0.000 claims abstract 5
- 230000004663 cell proliferation Effects 0.000 claims abstract 3
- 101150011488 NAALADL2 gene Proteins 0.000 claims abstract 2
- 238000001727 in vivo Methods 0.000 claims abstract 2
- 101150026024 pkiB gene Proteins 0.000 claims abstract 2
- 150000001875 compounds Chemical class 0.000 claims 23
- 238000012360 testing method Methods 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 101000994505 Drosophila melanogaster cAMP-dependent protein kinase catalytic subunit 1 Proteins 0.000 claims 5
- 230000027455 binding Effects 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 5
- 230000026731 phosphorylation Effects 0.000 claims 5
- 238000006366 phosphorylation reaction Methods 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108700008625 Reporter Genes Proteins 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000002103 transcriptional effect Effects 0.000 claims 2
- 238000000018 DNA microarray Methods 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000004942 nuclear accumulation Effects 0.000 claims 1
- -1 saliva Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95785307P | 2007-08-24 | 2007-08-24 | |
| US60/957,853 | 2007-08-24 | ||
| US3603008P | 2008-03-12 | 2008-03-12 | |
| US61/036,030 | 2008-03-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010111116A true RU2010111116A (ru) | 2011-09-27 |
Family
ID=40387239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010111116/10A RU2010111116A (ru) | 2007-08-24 | 2008-08-20 | Pkib и naaladl2 в качестве генов-мишеней в терапии и диагностике рака предстательной железы |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120022128A1 (enExample) |
| EP (1) | EP2195425A4 (enExample) |
| JP (1) | JP2010536365A (enExample) |
| KR (1) | KR20100075452A (enExample) |
| CN (1) | CN101855346A (enExample) |
| BR (1) | BRPI0815757A2 (enExample) |
| CA (1) | CA2697512A1 (enExample) |
| RU (1) | RU2010111116A (enExample) |
| TW (1) | TW200920405A (enExample) |
| WO (1) | WO2009028521A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945848B2 (en) * | 2009-07-31 | 2015-02-03 | Chromocell Corporation | Methods and compositions for identifying and validating modulators of cell fate |
| KR101164645B1 (ko) * | 2011-10-07 | 2012-07-20 | 대한민국 | Ｇｃｐⅱ 돌연변이를 함유하는 알츠하이머 예방 및 치료용 약학적 조성물 |
| GB201303308D0 (en) * | 2013-02-25 | 2013-04-10 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| GB201304612D0 (en) * | 2013-03-14 | 2013-05-01 | Cancer Rec Tech Ltd | Diagnostic and prognostic biomarkers for prostate cancer and other disorders |
| AU2014375206B2 (en) * | 2014-01-03 | 2021-09-30 | Innosign B.V. | Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression. |
| KR101824303B1 (ko) | 2015-08-06 | 2018-01-31 | 부경대학교 산학협력단 | 종이형 전립선암 진단센서, 이의 제조방법, 및 이를 이용한 전립선암 진단방법 |
| CN114177296B (zh) * | 2021-12-16 | 2023-05-26 | 上海交通大学医学院附属第九人民医院 | Mpc的过表达或活性提高在制备预防和/或治疗前列腺癌的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| US20040175756A1 (en) | 2001-04-26 | 2004-09-09 | Avidia Research Institute | Methods for using combinatorial libraries of monomer domains |
| US20050048512A1 (en) | 2001-04-26 | 2005-03-03 | Avidia Research Institute | Combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP1432724A4 (en) | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
| WO2004029212A2 (en) | 2002-09-25 | 2004-04-08 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2005044976A2 (en) | 2003-06-20 | 2005-05-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| WO2005083118A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| EP2343384A3 (en) * | 2004-03-23 | 2012-01-04 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancer |
| WO2006026051A2 (en) * | 2004-08-03 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis, prognosis and for targeting the therapy of neuroblastoma |
| EP1907582B1 (en) * | 2005-07-27 | 2012-01-04 | Oncotherapy Science, Inc. | Ect2 as a therapeutic target for esophageal cancer |
| EP2336780A1 (en) * | 2005-07-27 | 2011-06-22 | Oncotherapy Science, Inc. | Genes and polypeptides relating to prostate cancers |
-
2008
- 2008-08-20 KR KR1020107006479A patent/KR20100075452A/ko not_active Withdrawn
- 2008-08-20 TW TW097131697A patent/TW200920405A/zh unknown
- 2008-08-20 RU RU2010111116/10A patent/RU2010111116A/ru not_active Application Discontinuation
- 2008-08-20 JP JP2010521579A patent/JP2010536365A/ja not_active Withdrawn
- 2008-08-20 CA CA2697512A patent/CA2697512A1/en not_active Abandoned
- 2008-08-20 EP EP08828317A patent/EP2195425A4/en not_active Withdrawn
- 2008-08-20 BR BRPI0815757-0A2A patent/BRPI0815757A2/pt not_active IP Right Cessation
- 2008-08-20 WO PCT/JP2008/065234 patent/WO2009028521A1/en not_active Ceased
- 2008-08-20 US US12/674,664 patent/US20120022128A1/en not_active Abandoned
- 2008-08-20 CN CN200880109851A patent/CN101855346A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009028521A1 (en) | 2009-03-05 |
| CA2697512A1 (en) | 2009-03-05 |
| CN101855346A (zh) | 2010-10-06 |
| BRPI0815757A2 (pt) | 2015-02-18 |
| KR20100075452A (ko) | 2010-07-02 |
| US20120022128A1 (en) | 2012-01-26 |
| TW200920405A (en) | 2009-05-16 |
| JP2010536365A (ja) | 2010-12-02 |
| EP2195425A4 (en) | 2011-01-19 |
| EP2195425A1 (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8753892B2 (en) | Phosphodiesterase 4D7 as prostate cancer marker | |
| US9109259B2 (en) | Detection method for novel ROS1 fusions | |
| US20110008346A1 (en) | Biomarkers for cardiovascular disease | |
| JP2009502115A5 (enExample) | ||
| EP2235205A1 (en) | Methods for controlling vasculogenesis | |
| KR20180082328A (ko) | 전립선 암 예측 방법 | |
| JP2006517092A (ja) | 心不全遺伝子の決定及び治療薬スクリーニング | |
| CN110484613A (zh) | 一种强直性脊柱炎早期诊断标志物 | |
| RU2011111551A (ru) | C12orf48 как ген-мишень для лечения и диагностики рака | |
| ATE419533T1 (de) | Verfahren/präparat zur erkennung von pankreaskrebs | |
| Xie et al. | Clinical significance of MiR-27a expression in serum exosomes in patients with heart failure | |
| Mubiru et al. | A Variant of the alpha‐methyl‐acyl‐CoA racemase gene created by a deletion in exon 5 and its expression in prostate cancer | |
| CN114582509A (zh) | 一种葡萄膜黑色素瘤预后风险评分模型及其应用 | |
| KR101238196B1 (ko) | 대장암의 간 전이 진단용 조성물 및 그 용도 | |
| JP2012170335A (ja) | 口腔扁平上皮癌の診断方法及び治療用組成物 | |
| CN116397020B (zh) | 生物标志物在预测磺酸类烷化剂诱导骨髓损伤敏感性中的应用 | |
| US20130225430A1 (en) | Methods and compositions for treatment of tox-3 and tff-1 mediated cancer pathogenesis | |
| RU2011111387A (ru) | Syngr4 в качестве генов-мишеней для терапии и диагностики рака | |
| RU2011111411A (ru) | Oip5 в качестве гена-мишени для терапии и диагностики рака | |
| KR20220107891A (ko) | 퇴행성 뇌질환에서 zbtb16의 용도 | |
| CN105233290A (zh) | C22orf26基因及其表达产物在制备帕金森诊疗试剂中的应用 | |
| WO2015194524A1 (ja) | Ｂ前駆細胞性急性リンパ芽球性白血病新規キメラ遺伝子 | |
| KR102897614B1 (ko) | 신규한 MFSD7-ATP5l 융합유전자 및 이의 용도 | |
| KR100763902B1 (ko) | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 | |
| US11497817B2 (en) | Senile dementia treatment formulation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20121217 |